ArticleChemistry & biodiversity2026
Six Undescribed Lanostane-Type Triterpenoids From Ganoderma lucidum.
Article in Chemistry & biodiversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Six previously undescribed lanostane triterpenoids (1-6), together with 21 known analogues (7-27) were isolated from the fruiting bodies of the medicinal fungus Ganoderma lucidum. Compounds 1-3 are lucidenate-type triterpenoids, whereas compounds 4-6 are ganoderate-type derivatives. The planar structures and relative configurations of the six new compounds were established by comprehensive analysis of HRESIMS and 1D & 2D NMR spectroscopic data. The absolute configurations of compounds 1-3 were determined by ECD calculations or the modified Mosher's method. On the basis of the single-crystal X-ray diffraction data for compound 7, together with biogenetic considerations, the absolute configurations at C-25 of compounds 4-6 were assigned as 25R. Evaluation of the isolated compounds for anti-inflammatory activity revealed no significant inhibition of LPS-induced nitric oxide (NO) production in RAW264.7 macrophages.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.